Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingwen Baidu Decoction (QBD) is a classical traditional Chinese medicine (TCM) formula widely utilized for its heat-clearing, detoxifying, and anti-inflammatory properties. It is composed of multiple herbal ingredients, including Gypsum Fibrosum, Cornu Bubali, Radix Rehmanniae, Rhizoma Coptidis, Fructus Gardeniae, Radix Platycodonis, Radix Scutellariae, Rhizoma Anemarrhenae, Radix Paeoniae Rubra, Radix Scrophulariae, Fructus Forsythiae, Herba Lophatheri, Cortex Moutan Radicis, and Radix Glycyrrhizae. QBD has been investigated for its therapeutic potential in treating acute lung injury (ALI), sepsis, influenza, and other inflammatory or infectious conditions. During the 2014 West African Ebola outbreak, the 302 Military Hospital of China sponsored a prospective clinical study evaluating the efficacy and safety of Qingwen Baidu Decoction combined with Xuebijing Injection for the treatment of Ebola virus disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingwenbaidu decoction.